ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Down 4.3%

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s share price was down 4.3% during mid-day trading on Monday . The company traded as low as $12.85 and last traded at $12.99. Approximately 16,193 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 86,073 shares. The stock had previously closed at $13.58.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ABVX. Piper Sandler assumed coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an "overweight" rating and a $42.00 price objective for the company. BTIG Research initiated coverage on ABIVAX Société Anonyme in a research note on Monday, May 20th. They issued a "buy" rating and a $43.00 target price on the stock. Morgan Stanley boosted their target price on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an "equal weight" rating in a research note on Thursday, April 11th. Finally, Guggenheim assumed coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued a "buy" rating and a $50.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.20.

ABIVAX Société Anonyme Trading Down 0.2 %

The firm has a fifty day moving average price of $14.41 and a 200-day moving average price of $13.14.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in ABIVAX Société Anonyme by 18.2% during the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock worth $12,113,000 after purchasing an additional 131,414 shares during the period. Kennedy Capital Management LLC grew its stake in ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock valued at $1,718,000 after acquiring an additional 31,331 shares during the period. Capstone Investment Advisors LLC grew its stake in ABIVAX Société Anonyme by 9.0% in the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock valued at $900,000 after acquiring an additional 5,199 shares during the period. BNP Paribas Financial Markets acquired a new stake in ABIVAX Société Anonyme in the first quarter valued at approximately $81,000. Finally, Rosalind Advisors Inc. acquired a new stake in ABIVAX Société Anonyme in the first quarter valued at approximately $5,411,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.